Abstract 1730P
Background
A constellation of a large attack surface of interconnected devices and cyberimmaturity renders healthcare ripe to cybercrime. These vulnerabilities and their consequences will be magnified by the exponential growth in artificial intelligence. We assess the impact and implications of a cyberattack on a national cancer centre.
Methods
On 14 May 2021 (day 0), the first national healthcare ransomware attack occurred within which all hospitals including Cork University Hospital (CUH) Cancer Centre was implicated. Contingency plans were only present in laboratory services who had previously experience information technology (IT) failures. Departmental handwritten logs of activity and responses for 700 days after the attack were reviewed.
Results
Following the attack, all IT systems were shut down. No hospital cyberattack emergency plan was in place. Within CUH, on day 0, all radiotherapy (RT) treatment stopped, outpatient activity fell by 50%, and elective surgery stopped. Haematology, biochemistry and radiology capacity fell by 90% (daily sample deficit (DSD) 2700 samples), 75% (DSD 2,250 samples), and 90% (100% mammography/PETscan) respectively. Histopathology reporting times doubled (7 to 15 days). or paused IT links. Outsourcing of radiology and radiotherapy (RT) commenced, alternative communication networks (e.g., proton mail; Siilo) were utilised and national conference calls for RT and clinical trials were established. 136 patients had interrupted RT: median gap day 6 days category 1, 10 days for remaining patients. By day 28, e-mail communication was restored. By day 210, reporting and data storage backlogs were cleared and over 2000 computers were checked/replaced by the Irish Army. Notification of patients and staff whose data was compromised is ongoing (day 720).
Conclusions
Cyberattacks have rapid, profound and protracted impacts. While laboratory and diagnostic deficits were readily quantified, the impact of disrupted/delayed care on patient outcomes is less readily quantifiable but likely to be much greater. As criminals and nation states weaponize the internet, cyberawareness and cyberattack plans need to be embedded in healthcare.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.J. Keogh: Financial Interests, Other, Travel, Accommodations, Expenses: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23